Next Article in Journal / Special Issue
Preliminary Studies on Validation of Calu-3 Cell Line as a Model for Screening Respiratory Mucosa Irritation and Toxicity
Previous Article in Journal
Influence of Hydrothermal Treatment on Physicochemical Properties and Drug Release of Anti-Inflammatory Drugs of Intercalated Layered Double Hydroxide Nanoparticles
Previous Article in Special Issue
Analytical Challenges and Regulatory Requirements for Nasal Drug Products in Europe and the U.S.
Article Menu

Export Article

Open AccessReview
Pharmaceutics 2014, 6(2), 249-267;

Drug-Eluting Nasal Implants: Formulation, Characterization, Clinical Applications and Challenges

Biopharmaceutics and Drug Delivery Lab, College of Pharmacy, 5968 College Street, P.O. Box 15000, Halifax, NS B3H 4R2, Canada
Queen Elizabeth II (QEII) Health Sciences Centre, 1278 Tower Road, Halifax, NS B3H 2Y9, Canada
Author to whom correspondence should be addressed.
Received: 26 January 2014 / Revised: 28 March 2014 / Accepted: 7 May 2014 / Published: 27 May 2014
(This article belongs to the Special Issue Respiratory and Nasal Drug Delivery)
Full-Text   |   PDF [582 KB, uploaded 27 May 2014]   |  


Chronic inflammation and infection of the nasal sinuses, also referred to as Chronic Rhinosinusitis (CRS), severely affects patients’ quality of life. Adhesions, ostial stenosis, infection and inflammation relapses complicate chronic sinusitis treatment strategies. Drug-eluting stents, packings or implants have been suggested as reasonable alternatives for addressing these concerns. This article reviewed potential drug candidates for nasal implants, formulation methods/optimization and characterization methods. Clinical applications and important considerations were also addressed. Clinically-approved implants (Propel™ implant, the Relieva stratus™ MicroFlow spacer, and the Sinu-Foam™ spacer) for CRS treatment was an important focus. The advantages and limitations, as well as future considerations, challenges and the need for additional research in the field of nasal drug implant development, were discussed. View Full-Text
Keywords: nasal; sinuses; rhinosinusitis; stents; implants; inserts; sustained-release nasal; sinuses; rhinosinusitis; stents; implants; inserts; sustained-release

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Parikh, A.; Anand, U.; Ugwu, M.C.; Feridooni, T.; Massoud, E.; Agu, R.U. Drug-Eluting Nasal Implants: Formulation, Characterization, Clinical Applications and Challenges. Pharmaceutics 2014, 6, 249-267.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top